Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (MDT) has launched a significant global post-market study named DISSECT-N to assess the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in treating thoracic aortic dissection. The study will enroll at least 200 patients across 45 sites in North America, Europe, and Asia Pacific, with a primary focus on technical procedure success and major adverse events within one month post-procedure. This initiative responds to a critical need in treating aortic dissection, aiming to provide valuable real-world evidence and improve patient outcomes.
Medtronic reports significant three-year outcomes from the Global SYMPLICITY Registry, demonstrating that renal denervation (RDN) with the Symplicity™ System leads to substantial and lasting reductions in blood pressure (BP) for hypertensive patients. Office systolic BP decreased by 17 mmHg, with two-thirds of patients initially over 180 mmHg achieving lower BP levels. These results, achieved while patients remained on an average of four anti-hypertensive medications, underscore RDN's efficacy and safety, with a renal artery stenosis incidence of only 0.3%.
Medtronic announces FDA approval for the Percept™ PC Deep Brain Stimulation (DBS) system, incorporating BrainSense™ technology. This innovation allows for chronic capture of brain signals while delivering therapy for conditions like Parkinson's disease and OCD. The device, first implanted at Mayo Clinic, enables personalized treatment through data-driven insights. Key features include MRI compatibility, smart battery, improved longevity, and enhanced patient programming. Medtronic aims to transform care standards with this groundbreaking technology.
Medtronic announces the CE mark approval for its Evolut TAVI system to treat severe aortic stenosis in low-risk patients, now including those with bicuspid aortic valves. This new indication allows treatment for patients at extreme, high, and intermediate risks of surgical mortality. The Evolut Low Risk Trial showed TAVI's safer profile and effective outcomes, with shorter hospital stays and improved quality-of-life scores. With over 500,000 annual cases of severe aortic stenosis in Western Europe, this approval significantly increases patient access to minimally invasive valve replacement options.
Medtronic and Foxconn have partnered to manufacture 10,000 Puritan Bennett™ 560 ventilators in the U.S. over the next year, following Medtronic's ventilator open-source initiative. With Foxconn meeting Medtronic's regulatory standards, the production will take place in Mount Pleasant, Wisconsin. This collaboration aims to enhance ventilator supply critical for COVID-19 patients, with the possibility of doubling production if necessary. The PB560 model, introduced in 2010, is essential for managing severe respiratory illnesses.
Medtronic (NYSE: MDT) announced positive results from the ABRE clinical study, assessing the Abre venous self-expanding stent for iliofemoral outflow obstruction. The study demonstrated a 2.0% rate of major adverse events and an 88.0% primary patency rate at 12 months. Notable secondary endpoints included 100.0% device success and a 92.4% freedom from target lesion revascularization rate. Though Abre is currently investigational in the U.S., it received CE Mark approval in April 2017, indicating effective treatment options for patients with significant venous conditions.
Medtronic plc (NYSE: MDT) announced advancements in its extended wear infusion set technology during the American Diabetes Association's 80th Scientific Sessions. This new infusion set can be used safely for up to 7 days, more than twice the lifespan of current 3-day sets. Clinical studies indicate improved insulin stability, reducing the risk of hyperglycemia. Patients can potentially save 5-10 vials of insulin annually. The product has received the CE Mark, and a pivotal trial in the U.S. is underway to study its safety and efficacy.
Medtronic has announced a significant funding agreement with Blackstone Life Sciences to enhance its research and development in diabetes management. The collaboration will provide $337 million over several years, focusing on innovative insulin delivery and sensor technologies. This investment aims to address unmet needs for the 22 million global Type 1 diabetes patients. Medtronic plans to fast-track multiple development programs while the funding will cover R&D expenses, with potential royalties in the low- to mid-single digits if commercialized.
Medtronic announced positive results from two pivotal clinical trials for its MiniMed™ 780G automated insulin pump aimed at improving Type 1 diabetes management. The U.S. trial, focusing on ages 14-75, showed 96% user satisfaction, no severe hypoglycemia, and an average A1C of 7.0%. A New Zealand trial highlighted a 13-point boost in Time in Range for less-controlled patients. Bluetooth connectivity for real-time glucose monitoring is also a feature. The findings will support an upcoming FDA Premarket Approval application.
Medtronic (NYSE:MDT) has received CE Marking for its MiniMed™ 780G insulin pump, designed for type 1 diabetes patients aged 7 to 80. This system automates insulin delivery via the SmartGuard™ algorithm, providing basal insulin and correction boluses every five minutes. It allows customizable glucose targets and features Bluetooth connectivity for real-time glucose monitoring. Clinical feedback highlights improved diabetes management and quality of life. The MiniMed 780G is set to ship in select European markets this fall but is still under investigation in the U.S.
